H
Hervé Decousus
Researcher at French Institute of Health and Medical Research
Publications - 126
Citations - 15863
Hervé Decousus is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Pulmonary embolism & Thrombosis. The author has an hindex of 42, co-authored 126 publications receiving 14343 citations. Previous affiliations of Hervé Decousus include Jean Monnet University & Casa Sollievo della Sofferenza.
Papers
More filters
Journal ArticleDOI
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more
TL;DR: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Journal ArticleDOI
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
Hervé Decousus,Alain Leizorovicz,Florence Parent,Y. Page,Bernard Tardy,Philippe Girard,Silvy Laporte,René Faivre,Bernard Charbonnier,Fabrice-Guy Barral,Yann Huet,Gérald Simonneau +11 more
TL;DR: In high-risk patients with proximal deep-vein thrombosis, the initial beneficial effect of vena caval filters for the prevention of pulmonary embolism was counterbalanced by an excess of recurrent deep-vesin thROMBosis, without any difference in mortality.
Journal ArticleDOI
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Buller,Hervé Decousus,Michael A. Grosso,Saskia Middeldorp,Martin H. Prins,Gary E. Raskob,Sebastian Schellong,Annelise Segers,Minggao Shi,Peter Verhamme,Phil Wells +10 more
TL;DR: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism.
Journal ArticleDOI
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
H. R. Büller,Bruce L. Davidson,Hervé Decousus,Alexander Gallus,Michael Gent,Franco Piovella,Martin H. Prins,Gary E. Raskob,A.E.M. van den Berg-Segers,R. Cariou,O. Leeuwenkamp,A. W. A. Lensing +11 more
TL;DR: Once-daily, subcutaneous administration of fondaparinux without monitoring is at least as effective and is as safe as adjusted-dose, intravenous administration of unfractionated heparin in the initial treatment of hemodynamically stable patients with pulmonary embolism.
Journal ArticleDOI
Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.
Silvy Laporte,Patrick Mismetti,Hervé Decousus,Fernando Uresandi,Remedios Otero,José Luis Lobo,Manuel Monreal +6 more
TL;DR: The clinical predictors identified in the present study should be included in any clinical risk stratification scheme to optimally adapt the treatment of PE to the risk of the fatal outcome.